Daiichi Sankyo to Collaborate with Maruishi Pharmaceutical on Commercialization of General Anaesthesia Analgesic, Remifentanil Injection Generic

Tokyo, Japan (June 23, 2015) - Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) and Maruishi Pharmaceutical Co., Ltd. (hereafter, Maruishi Pharmaceutical) today announced a collaboration to commercialize the general anaesthesia analgesic, Remifentanil injection generic, for which Maruishi Pharmaceutical is currently applying for a manufacture and marketing license.

Remifentanil injection is widely used as an opioid analgesic (μ-opioid receptor agonist) to manage general anaesthesia. It is an ultra short-acting analgesic used for general anaesthesia characterized by its potent analgesic action together with its superior ability to rapidly regulate pain.

Once Maruishi Pharmaceutical has acquired a license for the manufacturing and marketing of this drug, the plan is for Maruishi Pharmaceutical to handle its manufacture and Daiichi Sankyo to handle its marketing, while both companies will jointly conduct promotion activities.